Journals / Eskisehir Medical Journal / 2026 / Volume: 7 Issue: 3

The Evolution of FLASH Radiotherapy: Insights from a Comprehensive Bibliometric Analysis

Muhammed Emin Bedir(KARAMANOĞLU MEHMETBEY ÜNİVERSİTESİ)0000-0002-4428-1241
Fuzuli Tuğrul(Acibadem Eskisehir Hospital)0000-0001-9724-253X
Pages
—
Publication Date
2026-08-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The field’s trajectory is defined by strong international collaboration that is accelerating its translation toward the clinic, positioning FLASH RT as a potential paradigm shift in cancer treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: To perform a comprehensive bibliometric analysis of FLASH Radiotherapy (FLASH RT) research to map its intellectual landscape, identify key trends, and delineate the collaborative structures driving its evolution as a promising field in oncology.
📊
Key Findings & Data:Methods: A systematic search of the Web of Science Core Collection database was conducted for publications from 1980 to 2024, resulting in 2,584 documents.
💡
Conclusion & Impact:The field’s trajectory is defined by strong international collaboration that is accelerating its translation toward the clinic, positioning FLASH RT as a potential paradigm shift in cancer treatment.
🔬Design:Research Article
📍Scope:2024 Verileri
⚙️Variables:FLASH · Radiotherapy · Bibliometric Analysis

Abstract

Introduction: To perform a comprehensive bibliometric analysis of FLASH Radiotherapy (FLASH RT) research to map its intellectual landscape, identify key trends, and delineate the collaborative structures driving its evolution as a promising field in oncology. Methods: A systematic search of the Web of Science Core Collection database was conducted for publications from 1980 to 2024, resulting in 2,584 documents. The dataset was analyzed using the Bibliometrix R package to examine publication trends, thematic evolution, influential contributors, and international collaboration networks. Results: The analysis revealed an exponential growth in research (12.3% annually), especially since 2013. A significant thematic shift from foundational radiobiology to clinical applications was identified, marked by the rise of keywords like "clinical trial," "toxicity," and "quality of life." A core intellectual structure was defined, centered around key journals and influential preclinical studies. A strong transatlantic collaboration network, led by institutions in the USA and Europe, appears to be an important contributor to scientific productivity and knowledge dissemination. Conclusion: FLASH RT has rapidly evolved from a preclinical concept into a rapidly expanding and increasingly clinically oriented research field. The field’s trajectory is defined by strong international collaboration that is accelerating its translation toward the clinic, positioning FLASH RT as a potential paradigm shift in cancer treatment.

🔖

Cite This Article

Bedir, M. E., Tuğrul, F. (2026). The Evolution of FLASH Radiotherapy: Insights from a Comprehensive Bibliometric Analysis. Eskisehir Medical Journal, Volume: 7 Issue: 3. https://ajindex.com/articles/1614177

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (22)

  1. Vozenin MC, De Fornel P, Petersson K, Favaudon V, Jaccard M, Germond JF, Petit B, Burki M, Ferrand G, Patin D, et al. The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients. Clinical Cancer Research. 2019;25:35–42. doi: 10.1158/1078-0432.CCR-17-3375. PMID: 29875213.
  2. Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, Poupon MF, Brito I, Hupé P, Bourhis J, et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. 2014;6(245):245ra93. doi: 10.1126/SCITRANSLMED.3008973. PMID: 25031268.
  3. Bourhis J, Montay-Gruel P, Gonçalves Jorge P, Bailat C, Petit B, Ollivier J, Jeanneret-Sozzi W, Ozsahin M, Bochud F, Moeckli R, et al. Clinical translation of FLASH radiotherapy: Why and how? Radiotherapy and Oncology. 2019;139:11–17. doi: 10.1016/j.radonc.2019.04.008. PMID: 31253466.
  4. Montay-Gruel P, Petersson K, Jaccard M, Boivin G, Germond JF, Petit B, Doenlen R, Favaudon V, Bochud F, Bailat C, et al. Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with dose rates above 100 Gy/s. Radiotherapy and Oncology. 2017;124:365–369. doi: 10.1016/j.radonc.2017.05.003. PMID: 28545957.
  5. Velalopoulou A, Karagounis I V., Cramer GM, Kim MM, Skoufos G, Goia D, Hagan S, Verginadis II, Shoniyozov K, Chiango J, et al. Flash proton radiotherapy spares normal epithelial and mesenchymal tissues while preserving sarcoma response. Cancer Res. 2021;81:4808–4821. doi: 10.1158/0008-5472.CAN-21-1500. PMID: 34321243.
  6. Esplen N, Mendonca MS, Bazalova-Carter M. Physics and biology of ultrahigh dose-rate (FLASH) radiotherapy: A topical review. Phys Med Biol. 2020;65(23):23TR03. doi: 10.1088/1361-6560/ABAA28. PMID: 32721941.
  7. Bourhis J, Sozzi WJ, Jorge PG, Gaide O, Bailat C, Duclos F, Patin D, Ozsahin M, Bochud F, Germond JF, et al. Treatment of a first patient with FLASH-radiotherapy. Radiotherapy and Oncology. 2019;139:18–22. doi: 10.1016/j.radonc.2019.06.019. PMID: 31303340.
  8. Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: How great is the impact? Scientometrics. 2015;105:1809–1831. doi: 10.1007/S11192-015-1645-Z. PMID: 26594073.
  9. Mingers J, Leydesdorff L. A review of theory and practice in scientometrics. Eur J Oper Res. 2015;246:1–19. doi: 10.1016/J.EJOR.2015.04.002.
  10. Bornmann L, Daniel HD. What do citation counts measure? A review of studies on citing behavior. Journal of Documentation. 2008;64:45–80. doi: 10.1108/00220410810844150.
  11. Cobo MJ, López-Herrera AG, Herrera-Viedma E, Herrera F. An approach for detecting, quantifying, and visualizing the evolution of a research field: A practical application to the Fuzzy Sets Theory field. J Informetr. 2011;5:146–166. doi: 10.1016/J.JOI.2010.10.002.
  12. Grauwin S, Sperano I. Bibliomaps - a software to create web-based interactive maps of science: The case of UX map. Proceedings of the Association for Information Science and Technology. 2018;55:815–816. doi: 10.1002/PRA2.2018.14505501129.
  13. Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11:959–975. doi: 10.1016/J.JOI.2017.08.007.
  14. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–538. doi: 10.1007/S11192-009-0146-3. PMID: 20585380.
  15. Persson O, Danell R, Schneider JW. How to use Bibexcel for various types of bibliometric analysis. International Society for Scientometrics and Informetrics; 2009. p. 9–24. Available from: https://researchprofiles.ku.dk/en/publications/how-to-use-bibexcel-for-various-types-of-bibliometric-analysis.
  16. Cobo MJ, López-Herrera AG, Herrera-Viedma E, Herrera F. SciMAT: A new science mapping analysis software tool. Journal of the American Society for Information Science and Technology. 2012;63:1609–1630. doi: 10.1002/ASI.22688.
  17. Chen C. CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature. Journal of the American Society for Information Science and Technology. 2006;57:359–377. doi: 10.1002/ASI.20317.
  18. Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, et al. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. New England Journal of Medicine. 2010;362:513–520. doi: 10.1056/nejmoa0906260. PMID: 20147717.
  19. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–1094. doi: 10.1016/S1470-2045(13)70386-3. PMID: 24055415.
  20. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–1060. doi: 10.1016/S1470-2045(16)30102-4. PMID: 27339115.
  21. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–926. doi: 10.1016/S1470-2045(12)70265-6. PMID: 22877848.
  22. Mascia AE, Daugherty EC, Zhang Y, Lee E, Xiao Z, Sertorio M, Woo J, McCann C, Russell K, Levine L, et al. Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial. JAMA Oncol. 2023;9:62–69. doi: 10.1001/jamaoncol.2022.5843. PMID: 36273324